Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer.

Autor: Bonadio RC; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil. Electronic address: rrccbonadio@gmail.com., Costa FA; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Mendes SV; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Araujo BJ; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Nader-Marta G; Institut Jules Bordet, and l'Université Libre de Bruxelles (U.L.B)., Pinto PBC; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; AC Camargo Cancer Center, São Paulo, Brazil., Batista DN; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil., Testa L; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil., Ferrari MS; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Clinical breast cancer [Clin Breast Cancer] 2022 Dec; Vol. 22 (8), pp. e892-e900. Date of Electronic Publication: 2022 Aug 20.
DOI: 10.1016/j.clbc.2022.08.006
Abstrakt: Background: Special histological types (SHT) of triple-negative breast cancer (TNBC) are a heterogeneous group of rare poorly understood diseases. We aimed to evaluate the clinical features, treatment, and outcomes of patients with SHT of TNBC.
Methods: We evaluated patients with a SHT of TNBC treated in a cancer center between 2009 and 2020. The endpoints were characterization of clinical and pathological features, pathologic complete response (PCR) rate after neoadjuvant chemotherapy, disease-free survival (DFS), progression-free survival, and overall survival (OS).
Results: The 132 patients included had the following histologies: metaplastic (n=71), medullary pattern (n=14), lobular (n=12), adenoid cystic (n=12), apocrine (n=10), and others (n=13). Metaplastic, lobular, and medullary pattern tumors had higher grade (66.6-85.7% grade 3); adenoid cystic and apocrine had mainly grade 1-2 (70-83.3%). Metaplastic and lobular carcinomas had higher disease stages (47.8% and 58.2% stages III-IV). PCR rates were 10.3% for metaplastic and 33.3% for lobular carcinomas, with 5-year DFS rates of 56% and 51.4%. Medullary pattern carcinomas had a great response to treatment, with PCR rate of 100%, and 5-year DFS rate of 92.8%. Apocrine carcinomas also had favorable prognosis, with no recurrence after early disease treatment, and 5-year DFS rate of 83.3%. Adenoid cystic carcinomas had intermediate prognosis, with 5-year DFS rate of 66.6%.
Conclusion: SHT of TNBC encompasses heterogeneous malignancies with distinct behaviors. Lobular and metaplastic carcinomas showed high aggressiveness and poor treatment response, while medullary pattern and apocrine carcinomas had favorable outcomes. Treatment strategies focus on molecular features of each of these diseases are warranted.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: